Drug intelligence / Profile preview

SKM-104

Development stage: Preclinical
Lead developer: Skymab Biotherapeutics
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SKM-104 is an antibody-drug conjugate (ADC) initially developed by Skymab Biotherapeutics. It is currently in preclinical development, with its primary therapeutic focus on neoplasms, including both hematologic neoplasms and solid tumors. The drug is being explored for its potential use in the treatment of cancers that express G protein-coupled receptors (GPCRs), and combination strategies with checkpoint inhibitors, chemotherapy, or radiotherapy are under investigation[1][2]. The precise molecular target and mechanism of action have not been publicly disclosed as of the latest updates.

Targets

GPR1

Beyond the preview

Go deeper on SKM-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKM-104.

Explore the full profile